Proteomic characterization of exosomes from AD patients

AD 患者外泌体的蛋白质组学特征

• 批准号: 9563205
• 负责人: Robert A Rissman
• 金额: $ 84.4万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9563205
• 关键词: Alzheimer' s Disease; Amyloid; Amyloid beta-Protein; Biological Markers; Blood; Blood Proteins; Blood specimen; Clinical Trials Design; Collection; Diagnosis; Disease; Human; Intervention; Isotopes; Liquid Chromatography; Mass Spectrum Analysis; Methods; Molecular; Neurofibrillary Tangles; Pathogenicity; Pathway interactions; Patients; Peptides; Plasma; Positron-Emission Tomography; Post-Translational Protein Processing; Production; Proteins; Proteomics; Protocols documentation; Publishing; Resolution; Resources; Sampling; Signaling Protein; Source; base; biobank; differential expression; disease diagnosis; drug development; exosome; improved; power analysis; symptom treatment; tandem mass spectrometry; tau Proteins; tau-1; trafficking; treatment effect

PROJECT SUMMARY/ABSTRACT The pathogenic pathways involved in Alzheimer's disease (AD) involve β-amyloid (Aβ)- containing plaques and neurofibrillary tangles (NFTs) composed of phosphorylated tau protein. With only temporary, symptomatic treatments for AD available, effective disease-modifying intervention is desperately needed. The availability of protein signatures of AD may improve clinical trial design and analysis, increasing the likelihood of successful drug development by a better understanding and characterization of patients in trials. CNS derived exosomes may be a source of proteins that signal the progress of the disease. The precise mechanisms of exosome production and trafficking in AD are not understood, although the Rissman group and others have demonstrated the utility of exosomes as biomarkers and for prediction of treatment effects in human plasma. In this proposal, Drs. Rissman and Yates will use these unique resources to advance the understanding of exosome contents and trafficking to advance the field of AD diagnosis.

项目总结/摘要 阿尔茨海默病（AD）的致病途径涉及β-淀粉样蛋白（Aβ）- 含有由磷酸化tau蛋白组成的斑块和神经纤维缠结（NFT）。 只有暂时的，对症治疗AD，有效的疾病修饰 迫切需要进行干预。AD的蛋白质标签的可用性可能会提高 临床试验设计和分析，增加药物开发成功的可能性， 更好地理解和描述试验中的患者。CNS来源的外泌体可以是一种 蛋白质的来源，标志着疾病的进展。外泌体的确切机制 虽然Rissman小组和其他小组认为， 已经证明了外泌体作为生物标志物和用于预测治疗效果的效用 人体血浆中。在这项提案中，Rissman博士和Yates博士将利用这些独特的资源， 推进对外泌体内容和运输的理解，以推进AD领域 诊断.